TMPRSS6 knockdown suppresses malignant phenotypes in papillary thyroid carcinoma and alters macrophage polarization markers

Thyroid cancer is the most common form of cancer affecting the body's hormone glands, and the most frequent type is called papillary thyroid carcinoma. While many cases are slow-growing and treatable, a small percentage of patients develop tumors that return, spread to other parts of the body, or stop responding to standard therapies. To understand why some tumors become dangerous, scientists look not just at the cancer cells themselves, but at the neighborhood they live in, known as the tumor microenvironment. This neighborhood includes blood vessels, structural fibers, and various immune cells. Among these immune cells, macrophages are particularly important. Normally, these cells act as the body's cleanup crew, eating up debris and fighting infection. However, inside a tumor, they can be tricked into switching sides. Instead of attacking the cancer, they can transform into a supportive state that helps the tumor grow, spread, and hide from the immune system. This shift is often described as a change from a fighting mode to a helping mode.

Researchers at North China University of Science and Technology and several hospitals in Hebei province recently investigated a specific protein called TMPRSS6 to see if it plays a role in this dangerous neighborhood dynamic. They suspected that this protein, which is known to help regulate iron levels in the body, might also be involved in how thyroid cancer cells interact with the immune system. By studying human tissue samples, growing cancer cells in the lab, and testing them in mice, the team discovered that high levels of this protein are linked to more aggressive cancer behavior. More importantly, they found that when they removed this protein from the cancer cells, the cancer grew slower, and the nearby immune cells stopped acting like helpers and started acting more like fighters again.

The investigation began by looking at large public databases containing genetic information from thousands of patients. The researchers compared the genetic activity of thyroid tumors against normal thyroid tissue. They found that the gene responsible for making TMPRSS6 was significantly more active in the cancer tissues. When they looked closer at the immune landscape of these tumors, they noticed a clear pattern: the more TMPRSS6 was present, the more the immune cells resembled the "helping" type that supports tumor growth. Specifically, the data showed a strong link between high levels of this protein and markers associated with macrophages that have been co-opted by the tumor. This initial observation suggested that TMPRSS6 might be a key player in creating an environment where cancer can thrive.

To test if this connection was real and not just a statistical coincidence, the scientists moved to the laboratory. They used three different types of cells: two types of human papillary thyroid cancer cells and one type of normal thyroid cell. They confirmed that the cancer cells naturally produced much higher amounts of TMPRSS6 than the healthy cells. Next, they used a precise molecular tool to silence the gene that makes this protein in the cancer cells, effectively turning it off. Once the protein was removed, the behavior of the cancer cells changed dramatically. In standard tests designed to measure how fast cells multiply, the cells without TMPRSS6 grew much slower than the control group. Similarly, when the researchers tested the cells' ability to move and invade through barriers—a process that mimics how cancer spreads through the body—the cells lacking the protein were far less aggressive. They simply could not migrate or invade as effectively as the cells that still had the protein.

The study then explored how these cancer cells talk to the immune system. The researchers set up a unique experiment where they placed cancer cells in a special container above a layer of immune cells. The two groups were separated by a tiny mesh that allowed chemicals to pass through but kept the cells from touching. This setup let the scientists see how the cancer cells influenced the immune cells without direct contact. They used immune cells that had been coaxed into a neutral state and then exposed them to either normal cancer cells or cancer cells with the TMPRSS6 protein turned off. When the immune cells were exposed to the normal cancer cells, they adopted the "helping" profile, producing chemicals that encourage tumor growth and suppress the immune response. However, when the immune cells were exposed to the cancer cells with the protein silenced, their behavior shifted. They stopped producing the "helping" chemicals and began producing signals associated with the "fighting" mode, which is better at attacking tumors. This suggested that the cancer cells were using TMPRSS6 to send out signals that trained the immune system to be friendly to the cancer, and removing the protein broke that training.

To see if these findings held up in a living system, the team conducted an experiment using mice. They injected cancer cells into the skin of six mice, creating small tumors. Half of the mice received cancer cells with the normal protein, and the other half received cells where the protein had been silenced. Over the course of several weeks, the tumors in the mice with the silenced protein grew much more slowly. By the end of the study, the tumors in the treated group were roughly 59 percent smaller by weight than those in the control group. This result confirmed that removing TMPRSS6 could significantly slow down tumor growth in a living organism, even though the mice used in the experiment had immune systems that were too weak to show the full interaction between the cancer and the immune cells.

Despite these promising results, the researchers were careful to define the limits of their discovery. They noted that while they saw a clear change in the chemical signals sent between the cancer and immune cells, they did not identify the specific messenger molecule that carried the message. It remains possible that the protein affects the cancer cells directly, making them less aggressive, and also indirectly influences the immune system through a separate pathway. The study did not prove that one caused the other in a single, unbroken chain of events. Furthermore, because TMPRSS6 plays a vital role in regulating iron levels throughout the body, simply blocking it as a treatment could potentially disrupt the body's iron balance. The researchers concluded that while TMPRSS6 is a strong candidate for understanding how thyroid cancer becomes aggressive and how it manipulates the immune system, more work is needed to understand exactly how it works and whether it can be safely targeted for therapy. Their findings provide a solid foundation for future studies to explore how this protein shapes the tumor environment and to determine if it can be used to improve treatment for patients with difficult-to-treat thyroid cancer.